
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
Keywords: PF ها; EGFR; epidermal growth factor receptor; TKIs; tyrosine-kinase inhibitors; NSCLC; non-small-cell lung cancer; PFS; progression-free survival; FISH; fluorescence in-situ hybridization; IHC; immunohistochemistry; ERCC1; excision repair cross-complementation